NCT04441138 - Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions

Stage III Non-small-cell Lung Cancer

Interventions

DRUG

Durvalumab

Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease

Trial Locations (1)

60612

Rush University Cancer Center, Chicago